Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Oct;18(4):507–521. doi: 10.1111/j.1365-2125.1984.tb02498.x

Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

S C Mitchell, R H Waring, C S Haley, J R Idle, R L Smith
PMCID: PMC1463607  PMID: 6487492

Abstract

Interindividual variation in the sulphoxidation of S-carboxymethyl-L-cysteine (750 mg p.o.) was investigated in 200 healthy volunteers. Nearly a 100-fold difference was observed between individuals with respect to the amount of sulphoxide metabolites detected in their 0-8 h urine (0.6 to 59.1% recovery). Such a difference was shown to be reproducible over several months in 40 subjects who spanned the entire range of capacities. Cumulative plots and maximum likelihood analysis of the distribution indicated that a bimodal model was most probable. Analysis of pedigree data obtained from 12 families suggested a genetic effect with overlying environmental influences.

Full text

PDF
507

Images in this article

516Figure 4
on p.516

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnsley E. A., Eskin N. A., James S. P., Waring R. H. The acetylation of S-alkylcysteines by the rat. Biochem Pharmacol. 1969 Oct;18(10):2393–2401. doi: 10.1016/0006-2952(69)90354-2. [DOI] [PubMed] [Google Scholar]
  2. Barnsley E. A., Thomson A. E., Young L. Biochemical studies of toxic agents. 15. The biosynthesis of ethylmercapturic acid sulphoxide. Biochem J. 1964 Mar;90(3):588–596. doi: 10.1042/bj0900588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bray H. G., Caygill J. C., James S. P., Wood P. B. Formation of mercapturic acids. 5. Metabolism of some halogenoparaffins and nitroparaffins. Biochem J. 1964 Jan;90(1):127–132. doi: 10.1042/bj0900127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. EVANS D. A., WHITE T. A. HUMAN ACETYLATION POLYMORPHISM. J Lab Clin Med. 1964 Mar;63:394–403. [PubMed] [Google Scholar]
  5. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  6. Evans D. A., Harmer D., Downham D. Y., Whibley E. J., Idle J. R., Ritchie J., Smith R. L. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet. 1983 Oct;20(5):321–329. doi: 10.1136/jmg.20.5.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Homeida M., Halliwell M., Branch R. A. Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Clin Pharmacol Ther. 1978 Aug;24(2):228–232. doi: 10.1002/cpt1978242228. [DOI] [PubMed] [Google Scholar]
  9. Idle J. R., Ritchie J. C., Smith R. L. Oxidation phenotype and metiamide metabolism [proceedings]. Br J Pharmacol. 1979 Jul;66(3):432P–432P. [PMC free article] [PubMed] [Google Scholar]
  10. Idle J. R., Sloan T. P., Smith R. L., Wakile L. A. Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings]. Br J Pharmacol. 1979 Jul;66(3):430P–431P. [PMC free article] [PubMed] [Google Scholar]
  11. Lester R. H., Elston R. C., Graham J. B. Variations in levels of blood clotting factors IX and X in a population of normal men: possible genetic polymorphisms. Am J Hum Genet. 1972 Mar;24(2):168–180. [PMC free article] [PubMed] [Google Scholar]
  12. MURPHY E. A. ONE CAUSE?MANY CAUSES?THE ARGUMENT FROM THE BIMODAL DISTRIBUTION. J Chronic Dis. 1964 Apr;17:301–324. doi: 10.1016/0021-9681(64)90073-6. [DOI] [PubMed] [Google Scholar]
  13. Maclean C. J., Morton N. E., Elston R. C., Yee S. Skewness in commingled distributions. Biometrics. 1976 Sep;32(3):695–699. [PubMed] [Google Scholar]
  14. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  15. Murphy E. A., Bolling D. R. Testing of single locus hypotheses where there is incomplete separation of the phenotypes. Am J Hum Genet. 1967 May;19(3 Pt 1):322–334. [PMC free article] [PubMed] [Google Scholar]
  16. O'Malley K., Stevenson I. H., Crooks J. Impairment of human drug metabolism by oral contraceptive steroids. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):552–557. doi: 10.1002/cpt1972134552. [DOI] [PubMed] [Google Scholar]
  17. Panayi G. S., Huston G., Shah R. R., Mitchell S. C., Idle J. R., Smith R. L., Waring R. H. Deficient sulphoxidation status and D-penicillamine toxicity. Lancet. 1983 Feb 19;1(8321):414–414. doi: 10.1016/s0140-6736(83)91526-x. [DOI] [PubMed] [Google Scholar]
  18. Planas-Bohne F. Metabolism and pharmacokinetics of penicillamine in rats -- an overview. J Rheumatol Suppl. 1981 Jan-Feb;7:35–40. [PubMed] [Google Scholar]
  19. Populaire P., Terlain B., Pascal S., Lebreton G., Decouvelaere B. Résorption, excrétion et biotransformation chez le chien et chez le lapin, biotransformation chez l'homme de l'acide (méthyl-10 phénothiazinyl-2) acétique (acide métiazinique--16091 R.P) Arzneimittelforschung. 1969 Aug;19(8):1214–1221. [PubMed] [Google Scholar]
  20. Sklan N. M., Barnsley E. A. The metabolism of S-methyl-L-cysteine. Biochem J. 1968 Mar;107(2):217–223. doi: 10.1042/bj1070217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Taylor G., Houston J. B., Shaffer J., Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol. 1983 Mar;15(3):287–293. doi: 10.1111/j.1365-2125.1983.tb01501.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Turnbull L. B., Teng L., Kinzie J. M., Pitts J. E., Pinchbeck F. M., Bruce R. B. Excretion and biotransformation of carboxymethyl-cysteine in rat, dog, monkey and man. Xenobiotica. 1978 Oct;8(10):621–628. doi: 10.3109/00498257809069574. [DOI] [PubMed] [Google Scholar]
  23. Waring R. H., Mitchell S. C., Idle J. R., Smith R. L. Genetically determined impaired drug sulphoxidation. Lancet. 1981 Apr 4;1(8223):778–778. doi: 10.1016/s0140-6736(81)92647-7. [DOI] [PubMed] [Google Scholar]
  24. Waring R. H., Mitchell S. C., Shah R. R., Idle J. R., Smith R. L. Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man. Biochem Pharmacol. 1982 Oct 1;31(19):3151–3154. doi: 10.1016/0006-2952(82)90102-2. [DOI] [PubMed] [Google Scholar]
  25. Waring R. H., Mitchell S. C. The metabolism and elimination of S-carboxymethyl-L-cysteine in man. Drug Metab Dispos. 1982 Jan-Feb;10(1):61–62. [PubMed] [Google Scholar]
  26. Waring R. H. The metabolism of S-carboxymethylcysteine in rodents, marmosets and humans. Xenobiotica. 1978 May;8(5):265–270. doi: 10.3109/00498257809060949. [DOI] [PubMed] [Google Scholar]
  27. Waring R. H. Variation in human metabolism of S-carboxymethylcysteine. Eur J Drug Metab Pharmacokinet. 1980;5(1):49–52. doi: 10.1007/BF03189444. [DOI] [PubMed] [Google Scholar]
  28. West N. R., Rosenblum M. P., Sprince H., Gold S., Boehme D. H., Vogel W. H. Assay procedures for thioridazine, trifluoperazine, and their sulfoxides and determination of urinary excretion of these compounds in mental patients. J Pharm Sci. 1974 Mar;63(3):417–420. doi: 10.1002/jps.2600630322. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES